<VariationArchive VariationID="2829769" VariationName="NM_000264.5(PTCH1):c.746+2dup" VariationType="Duplication" Accession="VCV002829769" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-17" DateCreated="2024-02-20" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2990431" VariationID="2829769">
      <GeneList>
        <Gene Symbol="PTCH1" FullName="patched 1" GeneID="5727" HGNC_ID="HGNC:9585" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>9q22.32</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" start="95442980" stop="95516971" display_start="95442980" display_stop="95516971" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="9" Accession="NC_000009.11" start="98205263" stop="98279246" display_start="98205263" display_stop="98279246" Strand="-" />
          </Location>
          <OMIM>601309</OMIM>
          <Haploinsufficiency last_evaluated="2020-07-01" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PTCH1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-07-01" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PTCH1">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_000264.5(PTCH1):c.746+2dup</Name>
      <CanonicalSPDI>NC_000009.12:95481946:A:AA</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>9q22.32</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" start="95481946" stop="95481947" display_start="95481946" display_stop="95481947" variantLength="1" positionVCF="95481946" referenceAlleleVCF="T" alternateAlleleVCF="TA" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="9" Accession="NC_000009.11" start="98244228" stop="98244229" display_start="98244228" display_stop="98244229" variantLength="1" positionVCF="98244228" referenceAlleleVCF="T" alternateAlleleVCF="TA" />
      </Location>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_515" sequenceAccession="LRG_515">
            <Expression>LRG_515:g.40019dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000009.11" sequenceAccession="NC_000009" sequenceVersion="11" change="g.98244229dup" Assembly="GRCh37">
            <Expression>NC_000009.11:g.98244229dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000009.12" sequenceAccession="NC_000009" sequenceVersion="12" change="g.95481947dup" Assembly="GRCh38">
            <Expression>NC_000009.12:g.95481947dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007664.1" sequenceAccession="NG_007664" sequenceVersion="1" change="g.40019dup">
            <Expression>NG_007664.1:g.40019dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001354919.2" sequenceAccession="NM_001354919" sequenceVersion="2" change="c.550dup">
            <Expression>NM_001354919.2:c.550dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001341848.1" sequenceAccession="NP_001341848" sequenceVersion="1" change="p.Ter184LeuextTer?">
            <Expression>NP_001341848.1:p.Ter184LeuextTer?</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
          <MolecularConsequence ID="SO:0001578" Type="stop lost" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001083603.3" sequenceAccession="NM_001083603" sequenceVersion="3" change="c.743+2dup" MANEPlusClinical="true">
            <Expression>NM_001083603.3:c.743+2dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001083602.3" sequenceAccession="NM_001083602" sequenceVersion="3" change="c.548+2dup">
            <Expression>NM_001083602.3:c.548+2dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001354918.2" sequenceAccession="NM_001354918" sequenceVersion="2" change="c.746+2dup">
            <Expression>NM_001354918.2:c.746+2dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000264.5" sequenceAccession="NM_000264" sequenceVersion="5" change="c.746+2dup" MANESelect="true">
            <Expression>NM_000264.5:c.746+2dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001083605.3" sequenceAccession="NM_001083605" sequenceVersion="3" change="c.293+2dup">
            <Expression>NM_001083605.3:c.293+2dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001083604.3" sequenceAccession="NM_001083604" sequenceVersion="3" change="c.293+2dup">
            <Expression>NM_001083604.3:c.293+2dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001083606.3" sequenceAccession="NM_001083606" sequenceVersion="3" change="c.293+2dup">
            <Expression>NM_001083606.3:c.293+2dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001083607.3" sequenceAccession="NM_001083607" sequenceVersion="3" change="c.293+2dup">
            <Expression>NM_001083607.3:c.293+2dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000264.5(PTCH1):c.746+2dup AND Gorlin syndrome" Accession="RCV003610440" Version="1">
        <ClassifiedConditionList TraitSetID="940">
          <ClassifiedCondition DB="MedGen" ID="C0004779">Gorlin syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-05-08" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-05-08" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2024-02-20" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">17576681</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21514272</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9536098</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="940" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="381" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Basal cell nevus syndrome</ElementValue>
                <XRef ID="UWMG_1854558" DB="CSER _CC_NCGL, University of Washington" />
                <XRef Type="Phenotypic series" ID="PS109400" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gorlin syndrome</ElementValue>
                <XRef ID="69408002" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7166" />
                <XRef ID="7166" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Nevoid basal cell carcinoma syndrome (NBCCS) is characterized by the development of multiple jaw keratocysts, frequently beginning in the second decade of life, and/or basal cell carcinomas (BCCs) usually from the third decade onward. Approximately 60% of individuals have a recognizable appearance with macrocephaly, frontal bossing, coarse facial features, and facial milia. Most individuals have skeletal anomalies (e.g., bifid ribs, wedge-shaped vertebrae). Ectopic calcification, particularly in the falx, is present in more than 90% of affected individuals by age 20 years. Cardiac and ovarian fibromas occur in approximately 2% and 20% of individuals respectively. Approximately 5% of all children with NBCCS develop medulloblastoma (primitive neuroectodermal tumor), generally the desmoplastic subtype. The risk of developing medulloblastoma is substantially higher in individuals with an SUFU pathogenic variant (33%) than in those with a PTCH1 pathogenic variant (&lt;2%). Peak incidence is at age one to two years. Life expectancy in NBCCS is not significantly different from average.</Attribute>
                <XRef ID="NBK1151" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301330</ID>
                <ID Source="BookShelf">NBK1151</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGenetest, 2011">
                <ID Source="PubMed">21304560</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Skin Cancer">
                <ID Source="PubMed">26389333</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <XRef ID="377" DB="Orphanet" />
              <XRef ID="C0004779" DB="MedGen" />
              <XRef ID="MONDO:0007187" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS109400" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="8215587" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2024-02-20">
        <ClinVarSubmissionID localKey="18235588|MedGen:C0004779" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004424587" DateUpdated="2024-02-20" DateCreated="2024-02-20" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-05-08">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">21514272</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17576681</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9536098</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the PTCH1 protein in which other variant(s) (p.Glu237Lys) have been determined to be pathogenic (PMID: 21514272). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant results in skipping of exons 4-5, but is expected to preserve the integrity of the reading-frame (Invitae). This variant has not been reported in the literature in individuals affected with PTCH1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change falls in intron 5 of the PTCH1 gene. It does not directly change the encoded amino acid sequence of the PTCH1 protein. RNA analysis indicates that this variant induces altered splicing and likely results in a shortened protein product.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PTCH1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000009.11:g.98244228_98244229insA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0004779" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14200279</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="8215587" TraitType="Disease" MappingType="XRef" MappingValue="C0004779" MappingRef="MedGen">
        <MedGen CUI="C0004779" Name="Gorlin syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

